Scholar Rock Stock Forecast, Price & News

-3.18 (-9.29 %)
(As of 09/22/2021 04:00 PM ET)
Today's Range
50-Day Range
52-Week Range
Volume202,371 shs
Average Volume269,031 shs
Market Capitalization$1.07 billion
P/E RatioN/A
Dividend YieldN/A
30 days | 90 days | 365 days | Advanced Chart
Receive SRRK News and Ratings via Email

Sign-up to receive the latest news and ratings for Scholar Rock and its competitors with MarketBeat's FREE daily newsletter.

Scholar Rock logo

About Scholar Rock

Scholar Rock Holding Corp. is a biopharmaceutical company. It engages in the development and discovery of innovative medicines. The firm offers proprietary platform which designed to discover and develop monoclonal antibodies that have a high degree of specificity to achieve selective modulation of growth factor signaling. Its product candidate includes SRK-015 and SRK-181. The company was founded by Timothy A. Springer and Leonard I. Zon in October 2012 and is headquartered in Cambridge, MA.


See More Headlines

Industry, Sector and Symbol

Sales & Book Value






Overall MarketRank

2.36 out of 5 stars

Medical Sector

202nd out of 1,352 stocks

Biological Products, Except Diagnostic Industry

27th out of 193 stocks

Analyst Opinion: 3.5Community Rank: 4.1Dividend Strength: 0.0Insider Behavior: 4.2Valuation: 0.0 5 -4 -3 -2 -1 -
speech bubbles
speech bubbles

Scholar Rock (NASDAQ:SRRK) Frequently Asked Questions

Is Scholar Rock a buy right now?

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Scholar Rock in the last twelve months. There are currently 5 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" Scholar Rock stock.
View analyst ratings for Scholar Rock
or view top-rated stocks.

What stocks does MarketBeat like better than Scholar Rock?

Wall Street analysts have given Scholar Rock a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Scholar Rock wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

When is Scholar Rock's next earnings date?

Scholar Rock is scheduled to release its next quarterly earnings announcement on Monday, November 8th 2021.
View our earnings forecast for Scholar Rock

How were Scholar Rock's earnings last quarter?

Scholar Rock Holding Co. (NASDAQ:SRRK) issued its earnings results on Monday, August, 9th. The company reported ($0.84) EPS for the quarter, missing the consensus estimate of ($0.78) by $0.06. The business had revenue of $4.60 million for the quarter, compared to analysts' expectations of $5.25 million. Scholar Rock had a negative net margin of 687.82% and a negative trailing twelve-month return on equity of 55.58%. The company's revenue was up 17.9% on a year-over-year basis. During the same quarter in the prior year, the business earned ($0.65) EPS.
View Scholar Rock's earnings history

How has Scholar Rock's stock been impacted by COVID-19 (Coronavirus)?

Scholar Rock's stock was trading at $14.86 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization (WHO). Since then, SRRK stock has increased by 109.0% and is now trading at $31.06.
View which stocks have been most impacted by COVID-19

What price target have analysts set for SRRK?

5 brokerages have issued 1-year price objectives for Scholar Rock's stock. Their forecasts range from $39.00 to $79.00. On average, they anticipate Scholar Rock's share price to reach $61.60 in the next twelve months. This suggests a possible upside of 98.3% from the stock's current price.
View analysts' price targets for Scholar Rock
or view top-rated stocks among Wall Street analysts.

Who are Scholar Rock's key executives?

Scholar Rock's management team includes the following people:
  • Nagesh K. Mahanthappa, President, Chief Executive Officer & Director
  • Edward H. Myles, Chief Financial Officer & Head-Business Operations
  • Gregory J. Carven, Chief Scientific Officer
  • Yung H. Chyung, Chief Medical Officer
  • George G Nomikos, SVP-Medical & Clinical Science

Who are some of Scholar Rock's key competitors?

What other stocks do shareholders of Scholar Rock own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Scholar Rock investors own include Fulcrum Therapeutics (FULC), Coherus BioSciences (CHRS), CTI BioPharma (CTIC), Exelixis (EXEL), GlycoMimetics (GLYC), Nektar Therapeutics (NKTR), SCYNEXIS (SCYX), TG Therapeutics (TGTX), VBI Vaccines (VBIV) and Atara Biotherapeutics (ATRA).

When did Scholar Rock IPO?

(SRRK) raised $76 million in an initial public offering (IPO) on Thursday, May 24th 2018. The company issued 5,400,000 shares at a price of $13.00-$15.00 per share. Jefferies, Cowen and BMO Capital Markets acted as the underwriters for the IPO and Wedbush PacGrow was co-manager.

What is Scholar Rock's stock symbol?

Scholar Rock trades on the NASDAQ under the ticker symbol "SRRK."

Who are Scholar Rock's major shareholders?

Scholar Rock's stock is owned by many different institutional and retail investors. Top institutional investors include FMR LLC (15.00%), Price T Rowe Associates Inc. MD (13.99%), Redmile Group LLC (6.69%), Bellevue Group AG (6.68%), BlackRock Inc. (6.33%) and State Street Corp (5.05%). Company insiders that own Scholar Rock stock include Gregory John Carven, Jeffrey S Flier and Michael Gilman.
View institutional ownership trends for Scholar Rock

Which institutional investors are selling Scholar Rock stock?

SRRK stock was sold by a variety of institutional investors in the last quarter, including Marshall Wace North America L.P., Invesco Ltd., Deutsche Bank AG, Bank of New York Mellon Corp, Parametric Portfolio Associates LLC, Nuveen Asset Management LLC, Federated Hermes Inc., and Squarepoint Ops LLC. Company insiders that have sold Scholar Rock company stock in the last year include Gregory John Carven, Jeffrey S Flier, and Michael Gilman.
View insider buying and selling activity for Scholar Rock
or view top insider-selling stocks.

Which institutional investors are buying Scholar Rock stock?

SRRK stock was purchased by a variety of institutional investors in the last quarter, including State Street Corp, Price T Rowe Associates Inc. MD, Morgan Stanley, Morgan Stanley, Bellevue Group AG, Millennium Management LLC, Redmile Group LLC, and Victory Capital Management Inc..
View insider buying and selling activity for Scholar Rock
or or view top insider-buying stocks.

How do I buy shares of Scholar Rock?

Shares of SRRK can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Scholar Rock's stock price today?

One share of SRRK stock can currently be purchased for approximately $31.06.

How much money does Scholar Rock make?

Scholar Rock has a market capitalization of $1.07 billion and generates $15.40 million in revenue each year. The company earns $-86,480,000.00 in net income (profit) each year or ($2.81) on an earnings per share basis.

How many employees does Scholar Rock have?

Scholar Rock employs 119 workers across the globe.

What is Scholar Rock's official website?

The official website for Scholar Rock is

Where are Scholar Rock's headquarters?

Scholar Rock is headquartered at 620 MEMORIAL DRIVE 2ND FLOOR, CAMBRIDGE MA, 02139.

How can I contact Scholar Rock?

Scholar Rock's mailing address is 620 MEMORIAL DRIVE 2ND FLOOR, CAMBRIDGE MA, 02139. The company can be reached via phone at (857) 259-3860 or via email at [email protected].

This page was last updated on 9/22/2021 by Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.